February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab
Sep 11, 2023, 00:27

Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab

Polyak Lab recently shared on X/Twitter:

“Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for TNBC is out in Molecular Cancer Therapeutics today. Congrats to all the coauthors! And of course a lot more to be explored in the future.”

Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. - Polyak Lab

For the article click here.
Source: Polyak Lab/Twitter